New drug cocktail aims to fight Hard-to-Treat stomach cancers
NCT ID NCT07594548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding the experimental drug futibatinib to standard chemotherapy (paclitaxel) and an antibody (ramucirumab) is safe for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. The study will enroll 18 participants to find the best dose and watch for side effects. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
futibatinib (a targeted drug) combined with paclitaxel (chemotherapy) and ramucirumab (antibody therapy)
What this could lead to
If successful, this could lead to a new treatment option for advanced stomach or esophageal cancer that is not curable with surgery.
What could go wrong
This is a very early phase I trial with only 18 people, focused on safety and dosing. The combination may not work better than existing treatments, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••